Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(20):1438-1440; doi:10.1093/jnci/djj445
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Twombly, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twombly, R.
Related Collections
Right arrowCorrespondence about this Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Breast Cancer Gene Microarrays Pass Muster

Renee Twombly

The first 150 words of the full text of this article appear below.

Biology may trump anatomy when it comes to predicting a breast cancer patient's outcome, according to a new study of gene expression tests.

The research, published in the New England Journal of Medicine, tested five different gene expression profiles developed within the last six years—two are now commercially available—to answer a big question about these tests: Do independently developed gene screens agree or disagree in predicting outcome for an individual patient?

The research team, led by scientists from the University of North Carolina in Chapel Hill, found that four of the five tests predicted the survival outcomes in a 295-patient Dutch group. More surprisingly, these tests agreed with each other even though each tested a different set of genes (only one gene overlapped between the two commercially available tests). A second analysis found that each of the four gene expression tests performed better at predicting disease-free survival and overall . . . [Full Text of this Article]

Beyond ER, PR, and HER2

Digging Into Details

Testing Breast Cancer Genes

Wait and See, or What?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Correspondence about this Article

Re: Breast Cancer Gene Microarrays Pass Muster
Steven Shak, Gary Palmer, and Joffre Baker
J Natl Cancer Inst 2007 99: 572-573. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
S. Shak, G. Palmer, and J. Baker
Re: Breast Cancer Gene Microarrays Pass Muster
J Natl Cancer Inst, April 4, 2007; 99(7): 572 - 573.
[Full Text] [PDF]